ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
This study has been terminated.
(Lack of accrual)
Sponsor:
Tulane University Health Sciences Center
Collaborators:
Novartis
Board of Regents, State of Louisiana
Information provided by:
Tulane University Health Sciences Center
ClinicalTrials.gov Identifier:
NCT00993642
First received: October 9, 2009
Last updated: July 20, 2011
Last verified: September 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | December 2010 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |